Feline herpesvirus (FHV-1) is a cause of chronic recurrent infections that can cause severe eye disease. This research, funded by Winn Feline Foundation since 2010, examined several agents for usefulness as carriers for administration of a potential new antiviral agent, small interfering RNAs (siRNAs). siRNAs use the cell’s own machinery to inhibit viral replication through interfering with the function of essential FHV-1 genes. These investigators have proven that this approach works to inhibit FHV-1. The next step was to test various delivery agents for use in topical administration to the eyes, the site of chronic FHV-1 infection.
Three of the delivery agents tested were effective at facilitating cellular transfer of the siRNA and viral replication was inhibited. The agents were nontoxic and nonirritating. Unfortunately, none of the agents were effective at delivering the siRNA to the cells of the feline cornea. Winn has funded the next phase of this project as the search continues for another approach such as a nanoparticle delivery vehicle. [MK]
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Feline herpesvirus (FHV-1) is a cause of chronic recurrent infections that can cause severe eye disease. This research, funded by Winn Feline Foundation since 2010, examined several agents for usefulness as carriers for administration of a potential new antiviral agent, small interfering RNAs (siRNAs). siRNAs use the cell’s own machinery to inhibit viral replication through interfering with the function of essential FHV-1 genes. These investigators have proven that this approach works to inhibit FHV-1. The next step was to test various delivery agents for use in topical administration to the eyes, the site of chronic FHV-1 infection.